WebApr 14, 2024 · Based on data from MarketBeat, bluebird bio currently has an average rating of “Hold” and a consensus target price of $6.78. bluebird bio Stock Up 17.2 %. Shares of NASDAQ:BLUE opened at $3.27 on Friday. bluebird bio, Inc. has a 52 week low of $2.78 and a 52 week high of $8.58. The stock has a market capitalization of $347.83 … WebJun 14, 2024 · Bluebird will price Zynteglo, formerly known as LentiGlobin, at €1.575 million ($1.77 million) in Europe, the company said during an investor presentation Friday. Just like Novartis did with ...
Is bluebird bio Inc. (NASDAQ: BLUE) A Stock A New Investor …
Webbluebird bio, Inc. (BLUE) Stock Price, News, Quote & History - Yahoo Finance U.S. markets closed +8.00(+0.19%) Dow Futures 33,709.00 +50.00(+0.15%) Nasdaq Futures … Web1 day ago · Last year, Australian drugmaker CSL Ltd set the list price of its gene therapy for blood disorder hemophilia B at a record $3.5 million, while bluebird bio priced its gene … homeless pods cornwall
BLE Stock Price bluebird bio Inc. Stock Quote (Germany: Frankfurt ...
WebAug 19, 2024 · Zynteglo’s $2.8 million price tag marks a new high, but bluebird bio says the one-time gene therapy works out cheaper than current beta-thalassemia treatment options. Following a positive Advisory Committee outcome in June, the US Food and Drug Administration (FDA) granted full approval for Zynteglo (betibeglogene autotemcel, or … WebApr 20, 2024 · Bluebird set a $1.8 million price for its gene therapy, called Zynteglo, soon after winning European approval for severe beta thalassemia in June 2024. But manufacturing issues forced the company to delay … WebApr 10, 2024 · What happened to bluebird bio’s price movement after its last earnings report? bluebird bio reported an EPS of $0.38 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went down -24.537%. Which hedge fund is a major shareholder of bluebird bio? homeless playtime project